ArticleUltrasonography (Seoul, Korea)2026
Quantitative ultrasound attenuation imaging outperforms B-mode scoring for assessing hepatic steatosis.
Article in Ultrasonography (Seoul, Korea), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAccurate quantification of hepatic fat is essential for the management of metabolic dysfunction-associated steatotic liver disease; however, area under the receiver operating characteristic curve analysis is suboptimal for ordinal outcomes such as steatosis grade. This study compared the improved attenuation parameter (iATT) and the Hamaguchi score for hepatic steatosis assessment using the Obuchowski measure.
methodsThis prospective study enrolled 605 patients with chronic liver disease who underwent iATT measurement, Hamaguchi scoring, and magnetic resonance imaging-derived proton density fat fraction (MRI-PDFF) assessment between April 2021 and March 2024. iATT was measured using the ARIETTA 850 ultrasound system, whereas the Hamaguchi score was determined through blinded assessment of standardized images for hepatorenal contrast, liver brightness, deep attenuation, and vessel blurring. MRI-PDFF served as the reference standard, with thresholds defined as S0 (<5.2%), S1 (5.2% to <11.3%), S2 (11.3% to <17.1%), and S3 (≥17.1%). Diagnostic accuracy was evaluated using the Obuchowski measure, which weights pairwise comparisons across disease stages.
resultsBoth methods showed strong correlations with MRI-PDFF (iATT: ρ=0.814; Hamaguchi score: ρ=0.799; P=0.533) and demonstrated excellent diagnostic performance. The Obuchowski measure was significantly higher for iATT than for the Hamaguchi score at S1 (0.921 vs. 0.875, P<0.001), S2 (0.931 vs. 0.892, P<0.001), and S3 (0.911 vs. 0.870, P<0.001). iATT performed significantly better in patients with body mass index (BMI) <30 kg/m², whereas the Hamaguchi score showed relatively better performance for detecting S1 steatosis in patients with obesity (BMI ≥30 kg/m²).
conclusionThe Obuchowski measure demonstrated that iATT provided significantly better ordinal discriminatory performance than the Hamaguchi score for the assessment of hepatic steatosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.